OTC · LGNDZ

Ligand Pharmaceuticals, Inc.

Healthcare · Medical - Pharmaceuticals

$0.00

Up+$0.00 (+30.05%)

Updated Oct 11, 2026, 4:11 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 157.46K
P/E ratio: 99
Dividend yield: 0.00%
52-week range: $0.00 – $0.02
Volume: 1K
Avg. volume: 56.76K

Price performance · LGNDZ

LGNDZ price history

1M range · 2 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

Last close: $0.00
Period change: +47.83%
Period low: $0.00
Period high: $0.00

Daily close

View OHLC price history

LGNDZ OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Oct 7, 2026	$0.003	$0.0034	$0.003	$0.0034	1K
Sep 16, 2026	$0.0023	$0.0023	$0.0023	$0.0023	4.51K

Latest LGNDZ news

The latest Smart Investors Daily articles mentioning LGNDZ.

analystAug 17, 2026

Leerink Partners Initiates Coverage on Ligand Pharmaceuticals, Inc. (LGNDZ) with Outperform

analystJul 8, 2026

Stifel Reiterates Buy Rating on Ligand Pharmaceuticals, Inc. (LGNDZ)

Latest LGNDZ news

The latest Smart Investors Daily articles mentioning LGNDZ.

LGNDZ research

Overview

Company profile and research snapshot.

Company profile

LIGAND PHARMS INC CVR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: Buy
Average target: —
Implied upside: —
Analysts: 13

LGNDZ recent ratings
Date	Firm	Rating	Target
Sep 25, 2026	Barclays	Overweight	—
Sep 24, 2026	HC Wainwright & Co.	Buy	—
Sep 23, 2026	Citigroup	Buy	—
Aug 14, 2026	Leerink Partners	Outperform	—
Aug 7, 2026	RBC Capital	Outperform	—

Open full forecast

News briefing

No generated briefing is available yet.

SeekingAlpha · Apr 27, 2026